Chemclin Diagnostics Co. Ltd. A - Asset Resilience Ratio

Latest as of March 2026: 15.34%

Chemclin Diagnostics Co. Ltd. A (688468) has an Asset Resilience Ratio of 15.34% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

CN¥270.55 Million
≈ $39.59 Million USD Cash + Short-term Investments

Total Assets

CN¥1.76 Billion
≈ $258.12 Million USD All company assets

Resilience Assessment

Good
Financial Resilience Level

Asset Resilience Ratio Trend (2019–2025)

This chart shows how Chemclin Diagnostics Co. Ltd. A's Asset Resilience Ratio has changed over time. See 688468 financial flexibility score to measure the company's free cash flow as a share of total liabilities.

Liquid Assets Composition Over Time

This chart breaks down Chemclin Diagnostics Co. Ltd. A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 688468 stock market capitalisation.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥270.55 Million 15.34%
Total Liquid Assets CN¥270.55 Million 15.34%

Asset Resilience Insights

  • Good Liquidity Position: Chemclin Diagnostics Co. Ltd. A maintains a healthy 15.34% of assets in liquid form.
  • This level provides good financial flexibility while maintaining productive asset deployment.
  • The company has significant short-term investments, indicating active treasury management.

Chemclin Diagnostics Co. Ltd. A Industry Peers by Asset Resilience Ratio

Compare Chemclin Diagnostics Co. Ltd. A's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Cowealth Medical China Co.Ltd.
SHG:603122
Diagnostics & Research 2.25%
Integral Diagnostics Ltd
AU:IDX
Diagnostics & Research 0.03%
Monash Ivf Group Ltd
AU:MVF
Diagnostics & Research 1.60%
SCOPE FLUIDICS SA ZY-10
F:S84
Diagnostics & Research 32.55%
Avricore Health Inc
V:AVCR
Diagnostics & Research 1.78%
Sonic Healthcare Ltd
AU:SHL
Diagnostics & Research 0.13%
Australian Clinical Labs Ltd
AU:ACL
Diagnostics & Research 4.11%
Healius Ltd
AU:HLS
Diagnostics & Research 0.06%

Annual Asset Resilience Ratio for Chemclin Diagnostics Co. Ltd. A (2019–2025)

The table below shows the annual Asset Resilience Ratio data for Chemclin Diagnostics Co. Ltd. A.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 17.11% CN¥301.22 Million
≈ $44.08 Million
CN¥1.76 Billion
≈ $257.68 Million
-10.68pp
2024-12-31 27.78% CN¥509.00 Million
≈ $74.48 Million
CN¥1.83 Billion
≈ $268.10 Million
+1.97pp
2023-12-31 25.82% CN¥470.00 Million
≈ $68.78 Million
CN¥1.82 Billion
≈ $266.41 Million
-14.59pp
2022-12-31 40.41% CN¥643.00 Million
≈ $94.09 Million
CN¥1.59 Billion
≈ $232.84 Million
-2.43pp
2021-12-31 42.84% CN¥613.00 Million
≈ $89.70 Million
CN¥1.43 Billion
≈ $209.39 Million
+10.21pp
2020-12-31 32.63% CN¥328.57 Million
≈ $48.08 Million
CN¥1.01 Billion
≈ $147.33 Million
-15.68pp
2019-12-31 48.32% CN¥480.00 Million
≈ $70.24 Million
CN¥993.39 Million
≈ $145.36 Million
--
pp = percentage points

About Chemclin Diagnostics Co. Ltd. A

SHG:688468 China Diagnostics & Research
Market Cap
$362.15 Million
CN¥2.47 Billion CNY
Market Cap Rank
#13923 Global
#4144 in China
Share Price
CN¥6.17
Change (1 day)
+0.33%
52-Week Range
CN¥5.55 - CN¥8.94
All Time High
CN¥27.99
About

Chemclin Diagnostics Co., Ltd. engages in the research and development, production, and sale of clinical immune chemiluminescence diagnostic reagents and instruments. Its products include LiCAA series of diagnostic reagents based on photo-induced chemiluminescence and CC series based on enzymatic chemiluminescence diagnostic reagents and instruments, primarily used for infectious diseases, such a… Read more